{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:27:10Z","timestamp":1793827630703,"version":"4.6.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:p>\n                    A 79-year-old man underwent proton beam therapy (PBT) for hepatocellular carcinoma. During follow\u2013up, MRI demonstrated stable T2-weighted hyperintensity in the irradiated region without interval enlargement or mass formation. Five years after PBT, a new hepatocellular carcinoma developed elsewhere in the liver.\n                    <jats:sup>18<\/jats:sup>\n                    F\u2013FDG PET showed no apparent abnormal uptake in the irradiated region, whereas\n                    <jats:sup>18<\/jats:sup>\n                    F-fibroblast activation protein inhibitor\u201374 PET demonstrated persistent uptake. These findings may reflect chronic radiation\u2013induced fibroinflammatory changes and suggest that fibroblast activation protein inhibitor\u2013PET can visualize such changes even years after PBT.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006733","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:03:50Z","timestamp":1792775030000},"page":"1123-1124","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Five-Year Persistent 18F-FAPI-74 Uptake in Radiation-induced Hepatic Fibrosis Following Proton Beam Therapy for Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-6376","authenticated-orcid":false,"given":"Yuki","family":"Narita","sequence":"first","affiliation":[{"name":"Department of Radiation Physics and Technology, Southern Tohoku Proton Therapy Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Komori","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama"},{"name":"Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Adaniya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Southern Tohoku General Hospital, Koriyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Biofunctional Imaging, Fukushima Medical University, Fukushima"},{"name":"Department of Radiology, Southern Tohoku Drug Discovery and Cyclotron Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-019-0362-2","article-title":"Cancer\u2013associated fibroblasts in radiotherapy: challenges and new opportunities","volume":"17","author":"Wang","year":"2019","journal-title":"Cell Commun Signal"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fizgerald","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2021.02.015","article-title":"68Ga\u2013fibroblast activation protein inhibitor PET\/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer","volume":"158","author":"Zhao","year":"2021","journal-title":"Radiother Oncol"},{"key":"R5-20261104","first-page":"1683","article-title":"Dual\u2013tracer PET\/CT protocol with [18F]\u2013FDG and [68Ga] Ga\u2013FAPI\u201346 for cancer imaging: a proof of concept","volume":"63","author":"Roth","year":"2022","journal-title":"J Nucl Med"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"16261","DOI":"10.1038\/s41598-022-20447-6","article-title":"[68Ga] FAPI\u2013PET\/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno\u2013, and adenoidcystic carcinomas","volume":"12","author":"Guberina","year":"2022","journal-title":"Sci Rep"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/annrheumdis-2020-217408","article-title":"Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging","volume":"79","author":"Schmidkonz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/ph17060716","article-title":"The role of fibroblast activation protein inhibitor positron emission tomography in inflammatory and infectious diseases: an updated systematic review","volume":"17","author":"Albano","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI\u2013PET)","volume":"2","author":"Mori","year":"2024","journal-title":"Npj Imaging"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/RLU.0000000000000471","article-title":"Persistent intense MIBG activity in the liver caused by prior radiation","volume":"39","author":"Yang","year":"2014","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:30Z","timestamp":1793826030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006733","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-07-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}